



PACIFIC EDGE WINS PRESTIGIOUS INFINZ INVESTOR RELATIONS AWARD

Pacific Edge has been named as the winner of the NZX Emerging Leaders Best Investor Relations Award, at the prestigious INFINZ Awards dinner in Auckland on Tuesday night. The Award was open to all companies outside of the NZX20.

Judges said: "Pacific Edge clearly demonstrated alignment between its Investor Relations strategy and outcomes delivered, such as increased sell side coverage and conversion of interest to investment. During 2020, Pacific Edge kept the market informed as headlines came thick and fast taking advantage of the acceleration of Covid-19 trends - both for the company (telehealth) and in its engagement with shareholders/potential shareholders via increased virtual engagement. The combination of improved investor engagement and positive milestones for Pacific Edge has seen the company deliver excellent investor outcomes through 2020 with its share price re-rating strongly, liquidity improving and the number and diversity of shareholders increasing."

On accepting the Award, CEO of Pacific Edge, David Darling, said: "Our approach to investor relations is to be timely, clear and transparent. It has been our goal to educate and inform the market about our high performance Cxbladder products, our strong market competitive advantage and the complex world of reimbursement for healthcare technology. Our innovative Cxbladder bladder cancer diagnostic tests are breaking new ground – they are disrupting the traditional testing regime for bladder cancer and providing new, better and more accurate ways for bladder cancer to be detected and managed. Our primary market is the USA, so not only is it important for us to inform investors about our diagnostic tests and how they work, we also need to educate them about how the physicians adopt new technology and how the US healthcare market pays for it.

"The people at Pacific Edge globally are very passionate about what they do and they share this passion with our investors, many of whom have been with us since the day we listed and have supported us on our journey. In the last 12 months, we've achieved some significant commercial milestones and our task now is to grow adoption and usage of our tests and deliver value for our shareholders. Pacific Edge has a very bright future."

ENDS

For more information contact: David Darling, Chief Executive Officer, Pacific Edge Ltd, P: +64 (3) 479 5800

For media assistance, please contact: Jackie Ellis, P: +64 27 246 2505 E: jackie@ellisandco.co.nz

OVERVIEW www.pacifedge.co.nz www.pacifedgedx.com

Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer diagnostic company specialising in the discovery and commercialisation of diagnostic and prognostic tests for better detection and management of cancer. Its Cxbladder suite of non-invasive, simple to use and accurate diagnostic tests provide actionable results, and better detection and management of urothelial cancer. The company is developing and commercialising its range of Cxbladder bladder cancer tests globally through its wholly owned central laboratories in New Zealand and the USA. The company's products have been tested and validated in international multi-centre clinical studies.



ABOUT Cxbladder Triage www.cxbladder.com

Cxbladder Triage combines the power of the genomic biomarkers with additional phenotypic and clinical risk factors to accurately identify patients with haematuria who have a low probability of bladder cancer and may not require a more extensive urological evaluation. Cxbladder Triage is a tool for use by clinicians and physicians in primary evaluation of patients with haematuria and is intended to reduce the need for an expensive and invasive work-up in patients who have a low probability of having urothelial carcinoma.

ABOUT Cxbladder Detect www.cxbladder.com

Cxbladder Detect enables the non-invasive detection of bladder and other urinary tract cancers from a small volume of a patients' urine. Cxbladder Detect provides clinicians with a quick, cost effective and accurate measure of the presence of the cancer as an effective adjunct to cystoscopy.

ABOUT Cxbladder Monitor www.cxbladder.com

Cxbladder Monitor allows urologists to monitor bladder cancer patients for recurrence of the disease. Bladder cancer has a recurrence rate of 50-80% and requires life-long surveillance. Cxbladder Monitor accurately identifies patients with a prior history of urothelial cancer (UC) whose Cxbladder Monitor score shows that they have a low probability of recurrent urothelial carcinoma. Cxbladder Monitor is designed to be used as the preferred adjunct test to cystoscopy in the management of patients for ongoing evaluation of recurrent bladder cancer.

ABOUT Cxbladder Resolve www.cxbladder.com

Cxbladder Resolve identifies those patients who are likely to have aggressive or more advanced bladder cancer. Cxbladder Resolve, when used as part of the primary evaluation of haematuria and/or in conjunction with other Cxbladder tests (Triage, Detect), is designed to assist clinicians by accurately identifying patients with a high probability of having high grade or late stage bladder cancer, for whom alternative or expedited treatment options may be warranted, or who can be prioritised for further investigation in high throughput settings.

Refer to www.cxbladder.com for more information.